37 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 35105904 | Ovarian toxicity of carboplatin and paclitaxel in mouse carriers of mutation in BRIP1 tumor suppressor gene. | 2022 Feb 1 | 1 |
2 | 35626017 | Molecular Characterization of BRCA1 c.5339T>C Missense Mutation in DNA Damage Response of Triple-Negative Breast Cancer. | 2022 May 13 | 2 |
3 | 32720318 | Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer. | 2021 Feb 15 | 4 |
4 | 33098992 | Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial. | 2021 Jan | 1 |
5 | 33100178 | Predictive factors for carboplatin hypersensitivity reactions in gynecologic cancers: Effect of BRCA status. | 2021 Oct | 2 |
6 | 33377156 | Value of adjuvant chemotherapy and informed microscopic examination for occult gynecologic cancer detected upon risk-reducing salpingo-oophorectomy after chemotherapy for BRCA1/2-associated breast cancer: a case report. | 2021 Mar 3 | 1 |
7 | 33690902 | Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. | 2021 Jun 15 | 1 |
8 | 33896588 | Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. | 2021 Jul | 1 |
9 | 32194804 | Sensitization of Carboplatinum- and Taxol-Resistant High-Grade Serous Ovarian Cancer Cells Carrying p53, BRCA1/2 Mutations by Emblica officinalis (Amla) via Multiple Targets. | 2020 | 1 |
10 | 31080557 | Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk. | 2019 Apr 23 | 2 |
11 | 31213465 | Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. | 2019 Aug 15 | 3 |
12 | 31821346 | Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models. | 2019 | 1 |
13 | 33457057 | Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations. | 2019 Jul | 6 |
14 | 29713086 | Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. | 2018 May | 1 |
15 | 29804901 | Responses to carboplatin in BRCA1/2-mutated breast cancer. | 2018 Jul | 1 |
16 | 27765459 | Carboplatin-allergic patients undergoing desensitization: prevalence and impact of the BRCA 1/2 mutation. | 2017 May - Jun | 1 |
17 | 28222073 | A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. | 2017 Mar 28 | 1 |
18 | 28356425 | Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. | 2017 Aug 1 | 3 |
19 | 28577239 | Population pharmacokinetic analyses of the effect of carboplatin pretreatment on olaparib in recurrent or refractory women's cancers. | 2017 Jul | 2 |
20 | 28715532 | Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. | 2017 Oct 1 | 1 |
21 | 27060208 | The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair. | 2016 Jul 1 | 1 |
22 | 25481791 | Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. | 2015 Jan | 1 |
23 | 25499884 | Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells. | 2015 Aug 1 | 3 |
24 | 25665554 | Assessing the role of platinum agents in aggressive breast cancers. | 2015 Feb | 1 |
25 | 25847929 | Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. | 2015 Jun 10 | 1 |
26 | 24678242 | Host Cell Reactivation and Transcriptional Activation of Carboplatin-Modified BRCA1. | 2014 | 5 |
27 | 24842883 | Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. | 2014 Jun | 2 |
28 | 24887359 | Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. | 2014 May 15 | 1 |
29 | 23522120 | Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient. | 2013 Mar 22 | 1 |
30 | 23867999 | Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. | 2013 Aug 20 | 5 |
31 | 22778154 | Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. | 2012 Sep | 1 |
32 | 22967451 | [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial]. | 2012 Jun | 1 |
33 | 20878461 | The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs. | 2011 Feb | 1 |
34 | 21368455 | [PARP inhibitors for cancer therapy]. | 2011 Jan | 1 |
35 | 19955925 | Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? | 2009 Dec | 1 |
36 | 18547621 | Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. | 2008 Aug | 2 |
37 | 16099593 | In vitro platination of human breast cancer suppressor gene1 (BRCA1) by the anticancer drug carboplatin. | 2005 Sep 15 | 5 |